论文部分内容阅读
目的评价检测恶性肿瘤患者血清CA125、CA242、CA153水平的临床价值.方法用酶联免疫吸附法测定97例四种恶性肿瘤患者血清CA125、CA242、CA153的含量.结果:肺癌患者血清CA125、CA242、CA153水平明显高于正常对照组(P<0.01或P<0.05),肺腺癌患者血清CA125水平明显高于肺鳞癌(P<0.05),肺癌Ⅳ期患者血清三种肿瘤标志物含量明显高于Ⅲ期(P<0.01或P<0.05),宫颈癌和非何杰金氏淋巴瘤(NHL)患者血清CA125水平明显高于对照组(P<0.01或P<0.0